Physician profile
Robert D Lyons
NPI 1700935376
$1,897.71
in general payments reported to CMS, 2019-2025
10 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.78 · 2020: $25.65 · 2021: $287 · 2022: $412 · 2023: $409 · 2024: $562 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $920.22 | 2022-2025 | Clareon, Argos |
| Rxsight INC | $528.13 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Biotissue Holdings INC. | $130.00 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $93.33 | 2021-2022 | |
| Allergan, INC. | $68.14 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $61.49 | 2019-2021 | |
| Dompe US, INC. | $36.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $21.57 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $21.23 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $17.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.